QT-Interval Prolongation, Torsades de Pointes, and Heart Failure With EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Systematic Review
Clinical Lung Cancer · 2024-06 · 25 (4) · 285-318
DOI: 10.1016/j.cllc.2024.02.005 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical Lung Cancer, 2024-06. Verfasst von Bilal Khokhar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Global Evidence and Outcomes, Takeda Development Center Americas, Inc., Lexington, MA. Electronic address: Bilal.Khokhar@takeda.com. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Heart Failure, Lung Neoplasms, ErbB Receptors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceuticals America Inc.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
A systematic literature review was conducted to determine the incidence and mortality of QT-interval prolongation (QTp), torsades de pointes (TdP), and heart failure (HF) in patients with non-small cell lung cancer (NSCLC) who received epidermal growth factor receptor (EGFR) TKIs. Of 296 identified publications, 95 met eligibility criteria and were abstracted for QTp/TdP and HF outcomes (QTp/TdP: 83 publications, including 5 case study publications; HF: 79 publications, including 6 case study publications [involving 8 patients]). QTp incidence ranged from 0% to 27.8% in observational studies and from 0% to 11% in clinical trials, with no deaths due to QTp. There were no TdP events or deaths due to TdP. The incidence of HF ranged from 0% to 8%, and HF mortality rates ranged from 0% to 4%. Patients receiving treatment with EGFR TKIs should be monitored for signs of QTp, TdP, and HF per prescribing information. Standardized definitions and methods to improve monitoring of QTp, TdP, and HF-related events are needed in patients with NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Global Evidence and Outcomes, Takeda Development Center Americas, Inc., Lexington, MA. Electronic address: Bilal.Khokhar@takeda.com.
- Global Patient Safety Evaluation, Takeda Development Center Americas, Inc., Lexington, MA.
- Real-world Evidence and Patient Outcomes, CERobs Consulting, LLC, Wrightsville Beach, NC.
- Real-world Evidence and Patient Outcomes, CERobs Consulting, LLC, Wrightsville Beach, NC; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC.
- Global Evidence and Outcomes, Takeda Development Center Americas, Inc., Lexington, MA.
Förderung
- Takeda Pharmaceuticals America Inc
Zitieren
APA
Khokhar, B., Chiang, B., Iglay, K., Reynolds, K., Rodriguez-Ormaza, N., Spalding, W., & Freedland, E. (2024). QT-Interval Prolongation, Torsades de Pointes, and Heart Failure With EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Systematic Review. Clinical Lung Cancer, 25(4), 285-318. https://doi.org/10.1016/j.cllc.2024.02.005
Vancouver
Khokhar B, Chiang B, Iglay K, Reynolds K, Rodriguez-Ormaza N, Spalding W, et al. QT-Interval Prolongation, Torsades de Pointes, and Heart Failure With EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Systematic Review. Clinical Lung Cancer. 2024;25(4):285-318. doi:10.1016/j.cllc.2024.02.005
BibTeX
@article{Khokhar2024,
author = {Khokhar, Bilal and Chiang, Beatrice and Iglay, Kristy and Reynolds, Kamika and Rodriguez-Ormaza, Nidia and Spalding, William and Freedland, Eric},
title = {QT-Interval Prolongation, Torsades de Pointes, and Heart Failure With EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Systematic Review},
journal = {Clinical Lung Cancer},
year = {2024},
volume = {25},
number = {4},
pages = {285--318},
doi = {10.1016/j.cllc.2024.02.005}
}
EUVIMED